Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00281840 · OUTCOME

Time to Progression

Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer · Source last updated 2015-06-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
5 yrs after treatment

What was measured

The time to disease progression is calculated from the date of treatment. Data for patients who remain disease progression free are censored as of date when the last follow-up information is obtained.

Analysis population: Patients who received at least one treatment on study

Groups in this outcome

Bevacizumab With Docetaxel and Radiation Therapy

Radiation therapy will be delivered using standard once-daily fractionation, five days a week for 8 weeks. Bevacizumab is administered intravenously once on day 1 every two weeks during the course of radiation and up to one year following completion of radiation therapy, at which point bevacizumab will be discontinued.Patients meeting planned neck dissection criteria, will not receive bevacizumab therapy following completion of concurrent chemo-radiation therapy (for at least 8 weeks prior to surgery). Bevacizumab therapy will restart 4 weeks after planned neck dissection for nine months.Docetaxel is administered intravenously once per week only during the course of radiation.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bevacizumab With Docetaxel and Radiation Therapy30

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Bevacizumab With Docetaxel and Radiation Therapy44.2Not reported33.7954.61Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        33.79
        upper Limit
        54.61
        value
        44.2
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
The time to disease progression is calculated from the date of treatment. Data for patients who remain disease progression free are censored as of date when the last follow-up information is obtained.
dispersion Type
95% Confidence Interval
groups
  1. description
    Radiation therapy will be delivered using standard once-daily fractionation, five days a week for 8 weeks. Bevacizumab is administered intravenously once on day 1 every two weeks during the course of radiation and up to one year following completion of radiation therapy, at which point bevacizumab will be discontinued.Patients meeting planned neck dissection criteria, will not receive bevacizumab therapy following completion of concurrent chemo-radiation therapy (for at least 8 weeks prior to surgery). Bevacizumab therapy will restart 4 weeks after planned neck dissection for nine months.Docetaxel is administered intravenously once per week only during the course of radiation.
    id
    OG000
    title
    Bevacizumab With Docetaxel and Radiation Therapy
param Type
MEAN
population Description
Patients who received at least one treatment on study
reporting Status
POSTED
time Frame
5 yrs after treatment
title
Time to Progression
type
PRIMARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice